viewCannPal Animal Therapeutics Ltd
A number of board members have purchased shares in the company in 2019 to date.
() founder and managing director Layton Mills has purchased 65,000 shares in the company via on-market trades.
The $10,075 parcel of shares increases Mills’ total holding in the company to over 7.57 million shares.
READ: CannPal Animal Therapeutics files new patent application as industry-leading research is recognised
The share purchase from Mills follows purchases from Max Johnston in March, chairman Geoff Starr in February, and Robert Clifford in January this year.
CannPal is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals such as dogs and cats.
CPAT-01 is the company’s lead drug candidate under development targeting pain and inflammation control in dogs.
ASX:CP1
Market: ASX
Market Cap: $13.5 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CannPal Animal Therapeutics Ltd named herein, including the promotion by the Company of CannPal Animal Therapeutics Ltd in any Content on the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
CannPal Animal Therapeutics leveraged to 'lucrative potential' of growing market
CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills speaks to Proactive Investors about the innovative pet pharmaceutical company, which operates in the medical cannabis space. "The goal for the company is really to develop products that can address clear,...
on 06/24/2018
2 min read
Prev article
3 min read
